155 related articles for article (PubMed ID: 31558067)
1. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with
Fazio F; Barberi W; Cazzaniga G; Fazio G; Messina M; Della Starza I; De Propris MS; Mancini F; Mohamed S; Del Giudice I; Chiaretti S; Moleti ML; Guarini A; Foà R; Testi AM
Leuk Lymphoma; 2020 Feb; 61(2):469-472. PubMed ID: 31558067
[No Abstract] [Full Text] [Related]
2. Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
Horiuchi M; Yoshida M; Yamasaki K; Sakagami R; Aoyama T; Tatsumi N; Tsutsumi M; Nakaya Y; Fuseya H; Yoshimura T; Hayashi Y; Nakao T; Yamane T
Ann Hematol; 2021 May; 100(5):1329-1331. PubMed ID: 33150465
[No Abstract] [Full Text] [Related]
3. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
4. [Acute lymphoblastic leukemia with EBF1-PDGFRB fusion gene: two cases report and literature review].
Chen YQ; Zheng YZ; Li J; Hua XL; Le SH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):69-71. PubMed ID: 36987727
[No Abstract] [Full Text] [Related]
5. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
[TBL] [Abstract][Full Text] [Related]
6. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
7. Early diagnosis of EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Ishihara T; Watakabe M; Ochi S; Akisada N; Nogami K
Pediatr Int; 2022 Jan; 64(1):e14955. PubMed ID: 35289450
[No Abstract] [Full Text] [Related]
8. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
9. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
[TBL] [Abstract][Full Text] [Related]
10. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
[No Abstract] [Full Text] [Related]
11. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
[TBL] [Abstract][Full Text] [Related]
13. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
[TBL] [Abstract][Full Text] [Related]
14.
Zhang Y; Gao Y; Zhang H; Zhang J; He F; Hnízda A; Qian M; Liu X; Gocho Y; Pui CH; Cheng T; Wang Q; Yang JJ; Zhu X; Liu X
Blood; 2018 May; 131(20):2256-2261. PubMed ID: 29434033
[TBL] [Abstract][Full Text] [Related]
15. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
[TBL] [Abstract][Full Text] [Related]
16. Improvement of Bone Marrow Necrosis by Tyrosine Kinase Inhibitor Substitution in a Pediatric Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Mikami T; Kato I; Oiki N; Okamoto S; Kamitori T; Tasaka K; Ogata H; Tanaka K; Umeda K; Hiramatsu H; Okamoto T; Adachi S; Takita J
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e539-e542. PubMed ID: 33843813
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy.
Mainor CB; Duffy AP; Atkins KL; Kimball AS; Baer MR
J Oncol Pharm Pract; 2016 Apr; 22(2):374-7. PubMed ID: 25616656
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
[No Abstract] [Full Text] [Related]
20. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.
Shimomura Y; Maruoka H; Ishikawa T
Int J Hematol; 2017 May; 105(5):697-701. PubMed ID: 28000100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]